-+ 0.00%
-+ 0.00%
-+ 0.00%

Bailey Tianheng announced that SysTimMune, a wholly-owned subsidiary of the company, previously reached a global strategic cooperation agreement with Bristol-Myers Squibb on Yizekang; its global phase III key registration clinical trial izabright-Lung02 has reached a milestone, officially triggering a second tranche of US$250 million with payment terms in the near future. SysTimMune will receive payment soon, and the actual payment amount must be deducted from bank charges.

Zhitongcaijing·09/21/2026 11:09:06
Listen to the news
Bailey Tianheng announced that SysTimMune, a wholly-owned subsidiary of the company, previously reached a global strategic cooperation agreement with Bristol-Myers Squibb on Yizekang; its global phase III key registration clinical trial izabright-Lung02 has reached a milestone, officially triggering a second tranche of US$250 million with payment terms in the near future. SysTimMune will receive payment soon, and the actual payment amount must be deducted from bank charges.